2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k l m [n] o p q r s t u v w x y z

Abstract Number: 475

N-3 Polyunsaturated Fatty Acids in Fat-1 Mice Attenuate Collagen Antibody-Induced Arthritis
Abstract Number: 2582

N-Acetylcysteine Regulates Osteoclastogenesis and Th17 Cell Differentiation in Rheumatoid Arthritis
Abstract Number: 2917

Nailfold Capillaroscopy and Mortality in Systemic Sclerosis
Abstract Number: 2165

Natural Language Processing to Rapidly Identify Potential Signals for Adverse Events Using Electronic Medical Record Data: Example of Arthralgias and Vedolizumab
Abstract Number: 2848

Near Patient Anti-Nuclear Antibody Multiplex Testing Using Whole Blood for the Diagnosis of Connective Tissue Diseases in a Tertiary Care Center
Abstract Number: 922

Negative Regulation of IL-17 Receptor Signaling By Regnase-1 Limits Immunopathology in a Mouse Model of Psoriatic Skin Disease
Abstract Number: 1047

Negative Results of Antinuclear Antibody (ANA) Testing in Clinical Trials of Systemic Lupus Erythematosus (SLE) May be Due to Assay Variability
Abstract Number: 2265

NET-Inducing Capacity Is a Biomarker in ANCA-Associated Vasculitis Independent of ANCA Antibodies
Abstract Number: 589

Netosis-Derived Products Might Have Diagnostic Potential for Disease Activity, Atherosclerosis and Analysis of Therapeutic Effectiveness in Rheumatoid Arthritis Patients
Abstract Number: 1437

Netrin-1 and Its Receptor Unc5b Are Novel Targets for the Treatment of Inflammatory Arthritis
Abstract Number: 1627

Network Meta-Analysis to Assess the Relative Efficacy of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Combination Therapy for Patients with Active Rheumatoid Arthritis Despite Conventional Dmards
Abstract Number: 1348

Neuromyelitis Optica: Patient Characteristics and Treatment Patterns Among Rheumatologists Versus Non-Rheumatologists
Abstract Number: 3102

Neutrophil Subsets, Arterial Inflammation, and Vascular Stiffness in Patients with Systemic Lupus Erythematosus
Abstract Number: 2853

Neutrophilia in Systemic Lupus Erythematosus As a Potential Indicator of Disease Activity
Abstract Number: 233

New Cardiovascular Risk Factors Screening in Patients with Gout
Abstract Number: 872

New Insights into the Pathogenesis of Giant Cell Arteritis through a Genome-Wide Association Study
Abstract Number: 1359

New Markers for Celiac Disease: Anti-Neo-Epitope Human and Microbial Transglutaminases
Abstract Number: 2763

New Treatment Option for SAPHO?
Abstract Number: 2415

Next Generation Sequencing Analysis of Familial Haemophagocytic Lymphohistiocytosis (HLH) Related Genes in Macrophage Activation Syndrome (MAS) and Secondary HLH (secHLH)
Abstract Number: 2868

NK Cell Characterization in Patients with Systemic Lupus Erythematosus: Increased Frequency of Ki67+ NK Cells Associated with Disease Activity and Type I Interferon Signature
Abstract Number: 254

NLRP12 Autoinflammatory Disease: A Chinese Case Series and Literature Review
Abstract Number: 2075

No Detection of Varicella-Zoster Virus in Temporal Arteries of Patients with Giant Cell Arteritis
Abstract Number: 1864

No Evidence of Association of ATP8B4 F436L missense Variant in a Large Systemic Sclerosis Cohort
Abstract Number: 1957

No Increased Risk of Chronic Kidney Disease with Allopurinol Use
Abstract Number: 962

No Increased Risk of Inflammatory Bowel Disease Among Secukinumab-Treated Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies
Abstract Number: 2636

No Strong Evidence Supporting Predictors for Successful Dose Reduction or Discontinuation of a Biologic in Rheumatoid Arthritis: A Systematic Review
Abstract Number: 2098

Non-Criteria Anti-Phospholipid Antibodies in SLE Patients
Abstract Number: 3073

Non-Additive Interaction of the Glucokinase Regulatory Protein and APOBEC1 Complementation Factor Loci with Alcohol Consumption to Influence the Risk of Gout
Abstract Number: 2830

Non-Calcified Coronary Artery Plaque Associates with Adverse Lipoprotein Profiles in Systemic Lupus Erythematosus
Abstract Number: 1062

Non-Conventional Antiphospholipid Antibodies in Patients with Clinical Obstetrical APS: Prevalence and Pregnancies Treatment Efficacy
Abstract Number: 1115

Non-Esterified Fatty Acids Are Associated with Clinical Features and an Enhanced Th1 Response in Rheumatoid Arthritis: Towards Disease Profiling
Abstract Number: 1863

Non-Invasive Investigation of Perfusion, Microvascular Structure, Erythema, Oxidative Stress and Oxygenation in Healthy Controls and in Patients with Primary and Secondary Raynaud’s Phenomenon
Abstract Number: 1997

Non-Medical Switch from Originator to Biosimilar Infliximab in Patients with Inflammatory Arthritis – Impact on s-Infliximab and Antidrug-Antibodies. Results from the Danish Rheumatologic Biobank and the Danbio Registry
Abstract Number: 483

Non-Steroidal Anti-Inflammatory Drugs Are More Beneficial Than Anti-Tnfα Drugs on the Radiographic Damage in Arthritis: A Study in Adjuvant Induced Arthritis
Abstract Number: 1087

Nonmemory B Cell Signature Alterations in Belimumab Patients
Abstract Number: 2877

Notch Ligand Delta-like Ligand 4 (DLL4) Expression on Dendritic Cells Is Increased in Systemic Lupus Erythematosus
Abstract Number: 59

Novel Agents for Blocking the Interaction of Immune Complexes with the Activatory FcγRIIIa Receptor
Abstract Number: 2984

Novel Anti-Malarial Drug Derivative Inhibited Type I Interferon Production and Autoimmune Inflammation through Inhibition of CGAS-Sting Pathway in Trex1-/- Mouse
Abstract Number: 2424

Novel Autoantigens for Anti- Endothelial Cell Antibodies in Pediatric Rheumatic Diseases Identified By Proteomics
Abstract Number: 46

Novel Composite Responder Endpoints for Fibromyalgia Therapy Assessment
Abstract Number: 1391

Novel Electronic Health Record-Based Method Confirms Increased Renal Disease Burden in Pediatric-Onset Vs. Adult-Onset Patients with Systemic Lupus Erythematosus
Abstract Number: 2832

Novel Gene Variants Associated with Cardiovascular Disease in Systemic Lupus Erythematosus
Abstract Number: 2789

Novel Glucocorticoid Prodrug Effectively Attenuates Late Stage Lupus Nephritis with Improved Safety Profile
Abstract Number: 916

Novel Immunosignature Stratifies Patients with Rheumatoid Arthritis into Distinct Disease Sub-Groups and Predicts Response to Anti-Tnfα Therapies
Abstract Number: 457

Novel Mechanism Mediated By the IL-23/Th17 Axis Contributing to Auto-Immune Arthritis
Abstract Number: 2154

Novel Pathogenic Functions of IL-11 on RA Joint Fibroblasts and Endothelial Cells
Abstract Number: 1756

Novel Role of Rho Kinase in Neutrophil Netosis during UVB Induced-Skin Inflammation
Abstract Number: 2034

Novel Susceptible Genes for Behçet’s Disease Identified By Dense Genotyping of Immune-Related Loci Implicate Host Responses to Microbial Exposure
Abstract Number: 717

NSAID Use and Functional Impairment in Ankylosing Spondylitis
Abstract Number: 434

Nurse Scheduled Telephone Visit: The Right Rheumatology Care for the Right Patient at the Right Time
Abstract Number: 189

Nutraceutical Therapy with Polyphenol-Rich Pomegranate Fruit Extract (POMx) Inhibits Systemic NFκB-Mediated Inflammation in a Murine Model of Endotoxemia

Jump to: View All • a b c d e f g h i j k l m [n] o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].